The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
|Articles|March 5, 2008
DermTech adds Allan C. Halpern, M.D., to company's melanoma advisory board
Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.
Advertisement
La Jolla, Calif.
- Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.
DermTech is developing molecular diagnostics for the early detection of melanoma and other diseases. Dr. Halpern is a widely recognized expert in the early detection and management of melanoma in high-risk patients, the Times reports.
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Advertisement
Advertisement
Trending on Dermatology Times
1
Galderma to Acquire ZO Skin Health for $1.5 Billion
2
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
3
Exosome Progress and Remibrutinib Label Expansion
4
Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life
5